Fuller & Thaler Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Fuller & Thaler Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-59,991	Closed	-$5.84M	–	801
2015 Q2	$5.84M	Buy	59,991 +1,258	+2%	+$120K	0.16%	112
2015 Q1	$5.49M	Sell	58,733 -191	-0.3%	-$16.3K	0.18%	123
2014 Q4	$5.24M	Buy	58,924 +877	+2%	+$63.9K	0.19%	126
2014 Q3	$4.01M	Hold	58,047	–	–	0.17%	144
2014 Q2	$3.33M	Sell	58,047 -8,655	-13%	-$439K	0.14%	170
2014 Q1	$2.65M	Sell	66,702 -7,753	-10%	-$332K	0.13%	187
2013 Q4	$3.12M	Buy	+74,455	New	+$2.16M	0.17%	173

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Fuller & Thaler Asset Management's MACK Position: Q3 2015 in Review

Fuller & Thaler Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 59,991 shares — an estimated $5.84M sold.

Fuller & Thaler Asset Management first reported a position in MACK in Q4 2013 and held it in 7 quarters. The position peaked at $5.84M in Q2 2015. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

Fuller & Thaler Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
Fuller & Thaler Asset Management sold 59,991 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $5.84M.
Fuller & Thaler Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 7 quarters.
Fuller & Thaler Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $5.84M in Q2 2015.
135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2015, filed 12 Nov 2015.